[1]万思聪.双胍类降糖药物治疗2型糖尿病的临床疗效及其对炎症因子的影响[J].医学信息,2022,35(16):135-137.[doi:10.3969/j.issn.1006-1959.2022.16.034]
 WAN Si-cong.The Clinical Efficacy of Metformin Hypoglycemic Agents in the Treatment of Type 2 Diabetes Mellitus and its Influence on Inflammatory Factors[J].Journal of Medical Information,2022,35(16):135-137.[doi:10.3969/j.issn.1006-1959.2022.16.034]
点击复制

双胍类降糖药物治疗2型糖尿病的临床疗效及其对炎症因子的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年16期
页码:
135-137
栏目:
药物与临床
出版日期:
2022-08-15

文章信息/Info

Title:
The Clinical Efficacy of Metformin Hypoglycemic Agents in the Treatment of Type 2 Diabetes Mellitus and its Influence on Inflammatory Factors
文章编号:
1006-1959(2022)16-0135-03
作者:
万思聪
(南昌市第一医院内分泌与代谢科,江西 南昌 330008)
Author(s):
WAN Si-cong
(Department of Endocrinology and Metabolism,Nanchang No.1 Hospital,Nanchang 330008,Jiangxi,China)
关键词:
双胍类降糖药物2型糖尿病炎症因子胰岛素抵抗指数
Keywords:
Metformin hypoglycemic agentsType 2 diabetes mellitusInflammatory factorsInsulin resistance index
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2022.16.034
文献标志码:
A
摘要:
目的 观察双胍类降糖药物对2型糖尿病治疗临床疗效及血糖控制效果。方法 选取2021年5月-2022年3月在我院诊治的94例2型糖尿病患者为研究对象,采用随机数字表法分为对照组(n=47)和观察组(n=47)。对照组采用常规治疗,观察组在常规治疗基础上采用盐酸二甲双胍缓释片治疗,比较两组临床疗效、血糖指标(空腹血糖、餐后2h血糖、糖化血蛋白)、胰岛素抵抗指数(HOMA-IR)、炎症因子水平[清白细胞介素6(IL-6)、C反应蛋白(CRP)及肿瘤坏死因子α(TNF-α)水平]以及不良反应发生率。结果 观察组临床治疗总有效率为95.74%,高于对照组的80.85%(P<0.05);两组治疗后空腹血糖、餐后2h血糖、糖化血红蛋白、IL-6、CRP、TNF-α均低于治疗前,且观察组低于对照组(P<0.05);两组治疗后HOMA-IR均小于治疗前,且观察组小于对照组(P<0.05);观察组不良反应发生率为6.38%,与对照组的8.51%比较,差异无统计学意义(P>0.05)。结论 盐酸二甲双胍缓释片治疗2型糖尿病临床疗效确切,具有较高的治疗总有效率。同时可促进血糖指标水平控制,降低胰岛素抵抗指数,减轻炎症因子反应,且不会增加不良反应,具有良好的应用有效性和安全性。
Abstract:
Objective To observe the clinical efficacy of biguanides in the treatment of type 2 diabetes mellitus and the effect of blood glucose control.Methods A total of 94 patients with type 2 diabetes mellitus who were treated in our hospital from May 2021 to March 2022 were selected as the research objects. They were randomly divided into control group (n=47) and observation group (n=47). The control group was treated with routine treatment, and the observation group was treated with metformin hydrochloride sustained-release tablets on the basis of routine treatment. The clinical efficacy, blood glucose indexes (fasting blood glucose, 2 h postprandial blood glucose, glycosylated blood protein), insulin resistance index (HOMA-IR), inflammatory factor levels [interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor α (TNF-α)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of clinical treatment in the observation group was 95.74%, which was higher than 80.85% in the control group (P<0.05). After treatment, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, IL-6, CRP and TNF-α in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The HOMA-IR of the two groups after treatment was less than that before treatment, and that in the observation group was less than the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.38 %, which was compared with 8.51% in the control group, the difference was not statistically significant (P>0.05).Conclusion Metformin hydrochloride sustained-release tablets have definite clinical efficacy in the treatment of type 2 diabetes, with high total effective rate. At the same time, it can promote the control of blood glucose index, reduce insulin resistance index, reduce inflammatory factor response, and do not increase adverse reactions, which has good application efficacy and safety.

参考文献/References:

[1]何煦芳,全会标,魏伟平,等.艾塞那肽联合二甲双胍治疗新诊断超重或肥胖2型糖尿病的疗效及后续观察[J].中南医学科学杂志,2017(4):58-59.[2]赵涛,乐静,李传静,等.二甲双胍对2型糖尿病胰岛素抵抗患者糖脂代谢及脂肪因子的影响[J].安徽医药,2017,20(7):1382-1385.[3]李天艺,李华,焦文君,等.二甲双胍对老年2型糖尿病炎症和肠道菌群失衡的临床疗效研究[J].中华老年医学杂志,2018,37(8):879-882.[4]Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the Ameri can Diabetes Association:national cross sectional study[J].BMJ,2020(369):m997.[5]那日苏,刘志文,马聪,等.格列美脲联合沙格列汀治疗2型糖尿病的疗效观察[J].现代药物与临床,2018,33(10):2585-2588.[6]杜少南.双胍类降糖药物对2型糖尿病治疗的临床疗效[J].实用糖尿病杂志,2020,20(12):312-314.[7]杨琼,王炜城.瑞舒伐他汀联合二甲双胍对2型糖尿病并发非酒精性脂肪肝患者肝功能和炎症因子的影响[J].药物评价研究,2020,43(1):107-110.[8]张四青,习燕华,钟树妹,等.格列美脲联合二甲双胍对新诊断2型糖尿病伴非酒精性脂肪肝病患者胰岛素抵抗和胰岛β细胞功能的影响[J].中国全科医学,2017,15(2):489-491.[9]温泉,钟兴,潘天荣,等.达格列净联合二甲双胍治疗2型糖尿病的疗效及对糖脂代谢的影响[J].现代生物医学进展,2020,29(9):372-374.[10]庾更绪,刘洋.双胍类降糖药物对2型糖尿病治疗的临床疗效[J].黑龙江医药科学,2018,15(10):224-226.[11]肖惟丹,袁志超.抗阻力运动联合双胍类降糖药物对2型糖尿病的治疗价值[J].中西医结合心血管病电子杂志,2018,28(8):86-88.[12]郑鹏.二甲双胍肠溶片联合格列齐特缓释片治疗2型糖尿病[J].吉林医药学院学报,2021,16(6):138-140.[13]李法宁,陈原,匡平,等.2种口服降糖药物联合胰岛素治疗初诊2型糖尿病的临床对比研究[J].中国医院药学杂志,2017,6(3):89-90.[14]李凤,翟晨辉,侯志梅.格列美脲对2型糖尿病患者代谢水平及血清IL-1β的影响[J].医学综述,2018,24(1):184-188.[15]李秀梅,杨秀红,董陆玲.西格列汀治疗二甲双胍不耐受的新诊断2型糖尿病临床观察[J].河北医药,2016,38(8):1189-1192.[16]Hwang S,Park J,Kim J,et al.Tissue expression of tubular in jury markers is associated with renal function decline in diabetic nephropathy [J].Journal of Diabetes&Its Complications,2017,31(12):1704-1709.[17]陈超,叶山东,邢学农,等.沙格列汀对2型糖尿病伴正常体重的代谢性肥胖患者体脂成分的影响[J].中国糖尿病杂志,2016,24(8):693-694.[18]王霖霞. 二甲双胍对2型糖尿病骨质疏松骨代谢影响及机制研究[D].石家庄:河北医科大学,2021.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
 HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(16):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
 DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(16):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(16):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(16):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
 LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(16):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
 LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(16):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
 DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(16):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(16):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
 LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(16):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
 BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(16):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 1900-01-01